Snyder, the panel's acting chair, splits on Capricor's Duchenne cell therapy — a rare-disease fault line the FDA must break by Aug. 22

Advisory committees vote on evidence; rare-disease panels increasingly vote on values. The 9-3 recommendation against Capricor's deramiocel at the Cellular, Tissue and Gene Therapies Advisory Committee meeting wasn't a clean defeat. It was a panel of methodologists and clinicians asked to do both jobs at once, with no rule for which standard wins when they diverge. That is the live question for the FDA before its Aug. 22 PDUFA action.

Deramiocel treats the cardiomyopathy that complicates Duchenne muscular dystrophy, a population with no approved heart therapy. HOPE-3 results were characterized in briefing materials as "fragile," sensitive to the choice of analysis. A statistician reads fragile evidence and sees noise a confirmatory trial might reverse. A clinician, in a population with no alternative, sees a door that may never reopen. The acting chair, Evan Snyder, voiced both readings in the same breath, an unusually candid public split that put the panel's real disagreement on the record instead of burying it in a count.

The FierceBiotech recap reports the 9-3. The substantive question is which standard the FDA inherits. If the agency defers to the methodological reading, it preserves evidentiary discipline and accepts that a rare-disease program without an alternative is collateral damage. If it leans on the clinical half, it sets a precedent that clinical need can override fragile surrogates in populations that cannot wait for the next trial. Either answer travels well beyond Duchenne heart cells, into every rare-disease cell therapy where the endpoint is a proxy and the alternative is nothing.